Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.37 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773661 | 0.92 | CAPN1 (0.43) | CAPN1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4136304 | 0.83 | CAPN1 (0.53) | CAPN1BMP1CCR1ADAM17EPHX2 | |
| SCHEMBL5434636 | 0.82 | CAPN1 (0.51) | CAPN1BMP1CCR1ADAM17EPHX2 | |
| SCHEMBL4127968 | 0.80 | CAPN1 (0.40) | CAPN1BMP1CCR1ADAM17EPHX2 | |
| SCHEMBL4139968 | 0.79 | CAPN1 (0.44) | CAPN1BMP1CCR1ADAM17EPHX2 | |
| SCHEMBL4130820 | 0.78 | CAPN1 (0.47) | CAPN1BMP1CCR1ADAM17CTSL | |
| SCHEMBL4141710 | 0.78 | CAPN1 (0.49) | CAPN1BMP1CCR1ADAM17CTSL | |
| SCHEMBL4142675 | 0.78 | CAPN1 (0.40) | CAPN1BMP1CCR1ADAM17TRPV4 | |
| SCHEMBL4129767 | 0.78 | CAPN1 (0.47) | CAPN1BMP1CCR1ADAM17CTSL | |
| SCHEMBL4142973 | 0.78 | CAPN1 (0.48) | CAPN1BMP1CCR1ADAM17EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CAPN1 2031/4885F2 4288/4885PRSS1 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.